In the ixekizumab every @ weeks group , sPGA @/@ was achieved by @ ( response rate @ % ; -LSB- effect size @ % ( @ % CI @-@ ) vs placebo ; @ % ( @-@ ) vs etanercept -RSB- ) and @ ( @ % ; -LSB- @ % ( @-@ ) vs placebo ; @ % ( @-@ ) vs etanercept -RSB- ) patients ; in the ixekizumab every @ weeks group by @ ( @ % ; -LSB- @ % ( @-@ ) vs placebo ; @ % ( @-@ ) vs etanercept -RSB- ) and @ ( @ % ; -LSB- @ % ( @-@ ) vs placebo ; @ % ( @-@ ) vs etanercept -RSB- ) patients ; in the placebo group by four ( @ % ) and @ ( @ % ) patients ; and in the etanercept group by @ ( @ % ) and @ ( @ % ) patients ( all p < @ vs placebo or etanercept ) .